22 January 2024
Latham & Watkins Advises BridgeBio Pharma in US$1.25 Billion Cross-Border Funding
Advising firms
Deal team
26 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Jekkie Kim Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Dan Van Fleet Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Hai Pham | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Katherine Webb | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Axel Magnusson | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Julia Steinberg | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Jack Gillen | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Billy Wu | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax | Not stated |
| Sam Yang | Latham & Watkins LLP | Associate | tax | Not stated |
| Reza Mojtabaee-Zamani | Latham & Watkins LLP | Partner | corporate and capital markets | Not stated |
| Drew Capurro | Latham & Watkins LLP | Partner | corporate and capital markets | Not stated |
| Sarah Axtell | Latham & Watkins LLP | Partner | corporate and capital markets | Not stated |
| Christopher Clark | Latham & Watkins LLP | Partner | corporate and capital markets | Not stated |
| Eric Rice | Latham & Watkins LLP | Partner | corporate and capital markets | Not stated |
| Raul Gonzalez | Latham & Watkins LLP | Associate | corporate and capital markets | Not stated |
| Shawn Noh | Latham & Watkins LLP | Associate | corporate and capital markets | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare regulatory | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | healthcare regulatory | Not stated |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Not stated |
| Mitch Bennett | Latham & Watkins LLP | Associate | data privacy | Not stated |
| Julie Crisp | Latham & Watkins LLP | Partner | ERISA | Not stated |
| Laura Ferrell | Latham & Watkins LLP | Partner | investment fund regulatory | Not stated |
| Jennifer Tian | Latham & Watkins LLP | Associate | investment fund regulatory | Not stated |
| Emily Yu | Latham & Watkins LLP | Counsel | security/intercreditor | Not stated |
Stated terms
- Stated value
- USD 1.25bn (US$1.25 billion)
- What the figure measures
- Total transaction value
- Client
- BridgeBio Pharma, Inc.Borrower
- Counterparties
- Blue Owl Capital (Investor)
Canada Pension Plan Investment Board (Investor)